liraglutide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
Glucagon-like Peptide (GLP) analogues	4164	204656-20-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: saxenda liraglutide [rDNA origin] liraglutide rDNA origin liraglutide [rNDA origin] injection liraglutide NN2211 victoza liraglutide recombinant	An analog of GLUCAGON-LIKE PEPTIDE 1 and agonist of the GLUCAGON-LIKE PEPTIDE 1 RECEPTOR that is used as a HYPOGLYCEMIC AGENT and supplemental therapy in the treatment of DIABETES MELLITUS by patients who do not respond to METFORMIN. Molecular weight: 3751.26 Formula: C172H265N43O51 CLOGP: LIPINSKI: None HAC: 94 HDO: 54 TPSA: 1513.76 ALOGS: ROTB: 130

Molecule

Description

Molfile Inchi Smiles

Synonyms:

saxenda
liraglutide [rDNA origin]
liraglutide rDNA origin
liraglutide [rNDA origin] injection
liraglutide
NN2211
victoza
liraglutide recombinant

An analog of GLUCAGON-LIKE PEPTIDE 1 and agonist of the GLUCAGON-LIKE PEPTIDE 1 RECEPTOR that is used as a HYPOGLYCEMIC AGENT and supplemental therapy in the treatment of DIABETES MELLITUS by patients who do not respond to METFORMIN.

Molecular weight: 3751.26
Formula: C172H265N43O51
CLOGP:
LIPINSKI: None
HAC: 94
HDO: 54
TPSA: 1513.76
ALOGS:
ROTB: 130

Drug dosage:

Dose	Unit	Route
40	U	P
1.50	mg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	6 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.01 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
CL (Clearance)	0.01 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.01 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	8.10 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company
Jan. 20, 2010	PMDA	Novo Nordisk Pharma Ltd
June 30, 2009	EMA
Jan. 25, 2010	FDA	NOVO NORDISK INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pancreatitis	2227.64	15.19	776	19227	41838	50543283
Pancreatitis acute	640.62	15.19	268	19735	23544	50561577
Nausea	535.52	15.19	974	19029	704424	49880697
Pancreatic carcinoma	420.87	15.19	138	19865	6076	50579045
Diabetic ketoacidosis	350.00	15.19	161	19842	17711	50567410
Vomiting	298.27	15.19	597	19406	460161	50124960
Lipase increased	273.39	15.19	109	19894	8432	50576689
Blood glucose increased	271.50	15.19	225	19778	71099	50514022
Injection site urticaria	166.65	15.19	86	19917	12131	50572990
Eructation	157.88	15.19	70	19933	7051	50578070
Injection site rash	149.29	15.19	88	19915	16089	50569032
Weight decreased	146.13	15.19	290	19713	220955	50364166
Abdominal pain	143.42	15.19	299	19704	235929	50349192
Injection site erythema	133.20	15.19	156	19847	74780	50510341
Pancreatic carcinoma metastatic	128.80	15.19	43	19960	1999	50583122
Cholelithiasis	124.33	15.19	110	19893	37863	50547258
Glycosylated haemoglobin increased	114.72	15.19	64	19939	10542	50574579
Ketoacidosis	108.47	15.19	45	19958	3850	50581271
Injection site pruritus	103.27	15.19	102	19901	40309	50544812
Diarrhoea	102.63	15.19	481	19522	587995	49997126
Diabetes mellitus inadequate control	101.99	15.19	64	19939	13081	50572040
Blood glucose decreased	98.81	15.19	71	19932	18140	50566981
Hypoglycaemia	97.59	15.19	113	19890	53468	50531653
Medullary thyroid cancer	94.00	15.19	19	19984	107	50585014
Euglycaemic diabetic ketoacidosis	93.75	15.19	37	19966	2782	50582339
Amylase increased	91.09	15.19	44	19959	5386	50579735
Dehydration	87.72	15.19	189	19814	152260	50432861
Papillary thyroid cancer	83.33	15.19	31	19972	1984	50583137
Thyroid mass	79.99	15.19	35	19968	3413	50581708
Injection site reaction	69.34	15.19	92	19911	49940	50535181
Abdominal pain upper	67.16	15.19	175	19828	159134	50425987
Adenocarcinoma pancreas	66.36	15.19	22	19981	1000	50584121
Drug ineffective	65.62	15.19	142	19861	819191	49765930
Lactic acidosis	65.21	15.19	73	19930	33282	50551839
Thyroid neoplasm	57.56	15.19	28	19975	3479	50581642
Acute kidney injury	56.41	15.19	208	19795	227850	50357271
Thyroid cancer	55.83	15.19	29	19974	4140	50580981
Decreased appetite	55.46	15.19	190	19813	200733	50384388
Weight loss poor	48.52	15.19	17	19986	915	50584206
Impaired gastric emptying	47.30	15.19	34	19969	8684	50576437
Reversible cerebral vasoconstriction syndrome	44.31	15.19	20	19983	2099	50583022
Injection site haematoma	43.25	15.19	28	19975	6032	50579089
Drug dose titration not performed	42.58	15.19	13	19990	451	50584670
Constipation	42.26	15.19	165	19838	185543	50399578
Systemic lupus erythematosus	41.13	15.19	4	19999	140618	50444503
Pancreatic neoplasm	41.02	15.19	14	19989	696	50584425
Pyrexia	38.24	15.19	57	19946	380146	50204975
Joint swelling	36.86	15.19	26	19977	245260	50339861
Neutropenia	36.69	15.19	7	19996	147958	50437163
Glossodynia	34.56	15.19	3	20000	115566	50469555
Flatulence	34.54	15.19	50	19953	29408	50555713
Pancreatic enzymes increased	34.07	15.19	12	19991	656	50584465
Rheumatoid arthritis	33.83	15.19	19	19984	202531	50382590
Pain	32.99	15.19	118	19885	578785	50006336
Cholecystitis acute	32.47	15.19	25	19978	7081	50578040
Pancreatic mass	32.28	15.19	12	19991	766	50584355
Cholecystitis	31.73	15.19	33	19970	13838	50571283
Abdominal distension	31.60	15.19	81	19922	72822	50512299
Drug titration error	31.27	15.19	11	19992	599	50584522
Infusion related reaction	31.17	15.19	14	19989	169543	50415578
Arthropathy	29.08	15.19	13	19990	157893	50427228
Pancreatic cyst	29.02	15.19	13	19990	1340	50583781
Drug intolerance	27.08	15.19	28	19975	219076	50366045
Glycosylated haemoglobin decreased	25.89	15.19	9	19994	473	50584648
Treatment failure	25.87	15.19	11	19992	137626	50447495
Completed suicide	25.67	15.19	10	19993	131879	50453242
Hyperglycaemia	25.46	15.19	49	19954	36356	50548765
Therapeutic product effect decreased	25.37	15.19	11	19992	136039	50449082
Mental disability	24.94	15.19	6	19997	82	50585039
Goitre	24.93	15.19	19	19984	5301	50579820
Injection site pain	24.69	15.19	98	19905	110926	50474195
Death	24.55	15.19	58	19945	325321	50259800
Palpitations	23.97	15.19	87	19916	94419	50490702
Febrile neutropenia	23.41	15.19	5	19998	97662	50487459
Ductal adenocarcinoma of pancreas	23.14	15.19	6	19997	113	50585008
Haemoglobin decreased	22.61	15.19	11	19992	127205	50457916
Hypoglycaemic unconsciousness	22.35	15.19	9	19994	713	50584408
Genotype drug resistance test positive	21.90	15.19	7	19996	283	50584838
General physical health deterioration	21.50	15.19	15	19988	142419	50442702
Bile acid malabsorption	21.38	15.19	6	19997	154	50584967
Disease progression	20.86	15.19	6	19997	95860	50489261
Pancytopenia	20.77	15.19	4	19999	84026	50501095
Huerthle cell carcinoma	20.51	15.19	3	20000	0	50585121
Lack of satiety	20.51	15.19	3	20000	0	50585121
Toxicity to various agents	20.23	15.19	33	19970	212466	50372655
Pancreatitis necrotising	19.82	15.19	10	19993	1343	50583778
Blood calcitonin increased	19.30	15.19	4	19999	26	50585095
Blood glucose abnormal	19.21	15.19	18	19985	6654	50578467
Cholangiocarcinoma	19.12	15.19	9	19994	1039	50584082
Wound	19.02	15.19	9	19994	105785	50479336
Aerococcus urinae infection	18.43	15.19	3	20000	3	50585118
Pneumonia	18.40	15.19	82	19921	378319	50206802
Infection	18.26	15.19	25	19978	172929	50412192
Renal failure	18.25	15.19	87	19916	106546	50478575
Injection site nodule	18.03	15.19	13	19990	3335	50581786
White blood cell count decreased	18.01	15.19	12	19991	116710	50468411
Maternal exposure during pregnancy	18.00	15.19	22	19981	159756	50425365
Stomatitis	17.65	15.19	9	19994	101335	50483786
Dysgeusia	17.65	15.19	44	19959	38872	50546249
Pancreatic pseudocyst	17.57	15.19	7	19996	539	50584582
Increased appetite	17.54	15.19	19	19984	8342	50576779
Swelling	17.48	15.19	33	19970	200839	50384282
Anaemia	17.47	15.19	47	19956	252409	50332712
Malignant neoplasm progression	17.36	15.19	3	20000	68121	50517000
Hepatic steatosis	17.27	15.19	33	19970	24351	50560770
Glomerular filtration rate decreased	17.02	15.19	22	19981	11630	50573491
Gastritis	16.79	15.19	39	19964	32944	50552177
C-reactive protein increased	16.78	15.19	3	20000	66471	50518650
Injection site swelling	16.65	15.19	45	19958	41728	50543393
Thrombocytopenia	16.12	15.19	16	19987	127657	50457464
Anuria	16.06	15.19	21	19982	11223	50573898
Diabetic ketosis	15.99	15.19	5	19998	188	50584933
Bile duct stone	15.91	15.19	12	19991	3295	50581826
Somnambulism	15.57	15.19	14	19989	4910	50580211
Diabetic retinopathy	15.25	15.19	10	19993	2200	50582921
Metastases to liver	15.22	15.19	28	19975	20076	50565045

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pancreatitis	1783.97	15.46	654	13478	33860	29526535
Pancreatitis acute	527.09	15.46	249	13883	24136	29536259
Pancreatic carcinoma	432.89	15.46	153	13979	6997	29553398
Nausea	335.75	15.46	537	13595	288718	29271677
Diabetic ketoacidosis	286.43	15.46	144	13988	15929	29544466
Pancreatic carcinoma metastatic	222.52	15.46	73	14059	2648	29557747
Lipase increased	220.17	15.46	98	14034	8239	29552156
Blood glucose increased	186.50	15.46	182	13950	58802	29501593
Vomiting	161.42	15.46	329	13803	211931	29348464
Glycosylated haemoglobin increased	140.62	15.46	75	14057	9351	29551044
Diabetes mellitus inadequate control	122.96	15.46	75	14057	12059	29548336
Adenocarcinoma pancreas	112.74	15.46	36	14096	1195	29559200
Weight decreased	109.78	15.46	230	13902	150675	29409720
Abdominal pain	108.74	15.46	215	13917	135142	29425253
Cholelithiasis	98.04	15.46	77	14055	18595	29541800
Eructation	92.79	15.46	43	14089	3963	29556432
Lactic acidosis	82.01	15.46	86	14046	30161	29530234
Amylase increased	75.89	15.46	41	14091	5239	29555156
Diarrhoea	74.79	15.46	335	13797	332363	29228032
Injection site rash	69.53	15.46	34	14098	3530	29556865
Papillary thyroid cancer	65.80	15.46	20	14112	562	29559833
Toxicity to various agents	61.43	15.46	6	14126	173655	29386740
Ketoacidosis	60.07	15.46	31	14101	3608	29556787
Pancreatitis necrotising	60.04	15.46	27	14105	2320	29558075
Hypoglycaemia	59.80	15.46	93	14039	48253	29512142
Abdominal pain upper	58.93	15.46	105	14027	60888	29499507
Acute kidney injury	57.12	15.46	264	13868	265003	29295392
Thyroid cancer	52.62	15.46	21	14111	1341	29559054
Weight loss poor	50.43	15.46	12	14120	127	29560268
Medullary thyroid cancer	46.64	15.46	9	14123	30	29560365
Pancreatic carcinoma stage IV	45.08	15.46	13	14119	303	29560092
Injection site haematoma	43.70	15.46	19	14113	1506	29558889
Dyspepsia	43.01	15.46	62	14070	30063	29530332
Metastases to liver	41.94	15.46	39	14093	11817	29548578
Pancreatitis chronic	41.53	15.46	20	14112	2008	29558387
Thyroid mass	41.43	15.46	13	14119	407	29559988
Injection site erythema	40.17	15.46	41	14091	13915	29546480
Pancreatic neoplasm	39.71	15.46	15	14117	826	29559569
Gastrooesophageal reflux disease	39.49	15.46	61	14071	31435	29528960
Injection site pruritus	39.34	15.46	28	14104	5821	29554574
Dehydration	37.26	15.46	130	14002	114618	29445777
Pneumonia	33.50	15.46	64	14068	320108	29240287
Pancreatic pseudocyst	33.23	15.46	13	14119	787	29559608
Pancreatic mass	32.63	15.46	13	14119	826	29559569
Febrile neutropenia	32.46	15.46	7	14125	112233	29448162
Neutropenia	31.14	15.46	12	14120	131699	29428696
Abdominal discomfort	30.10	15.46	69	14063	47834	29512561
Cholecystectomy	29.88	15.46	17	14115	2400	29557995
Tonsillar ulcer	28.80	15.46	8	14124	162	29560233
Product use in unapproved indication	28.20	15.46	4	14128	86871	29473524
Cholangiocarcinoma	27.76	15.46	12	14120	938	29559457
Pyrexia	27.10	15.46	61	14071	287561	29272834
Decreased appetite	27.07	15.46	139	13993	145203	29415192
Blood glucose decreased	26.93	15.46	31	14101	12038	29548357
Death	26.55	15.46	80	14052	342004	29218391
Flatulence	26.08	15.46	37	14095	17672	29542723
Blood calcitonin increased	26.07	15.46	5	14127	16	29560379
Ketosis	25.37	15.46	9	14123	414	29559981
Thyroid neoplasm	25.31	15.46	9	14123	417	29559978
White blood cell count decreased	24.50	15.46	5	14127	83357	29477038
Thyroid adenoma	24.35	15.46	4	14128	3	29560392
Injection site reaction	23.73	15.46	28	14104	11160	29549235
Glycosylated haemoglobin decreased	23.27	15.46	8	14124	335	29560060
Diabetic metabolic decompensation	23.19	15.46	12	14120	1404	29558991
Drug ineffective	22.76	15.46	93	14039	363077	29197318
Pancreatic enzymes increased	22.54	15.46	9	14123	575	29559820
Platelet count decreased	22.41	15.46	11	14121	104661	29455734
Haemoglobin decreased	22.30	15.46	12	14120	108363	29452032
Injection site urticaria	21.84	15.46	12	14120	1584	29558811
Constipation	21.81	15.46	110	14022	114050	29446345
Thrombocytopenia	21.10	15.46	20	14112	134803	29425592
Pancreatic cyst	20.51	15.46	9	14123	729	29559666
Completed suicide	20.06	15.46	9	14123	90237	29470158
Acinar cell carcinoma of pancreas	19.94	15.46	3	14129	0	29560395
Skin wound	19.92	15.46	7	14125	313	29560082
Ludwig angina	19.76	15.46	6	14126	168	29560227
Extrasystoles	19.69	15.46	15	14117	3459	29556936
Ductal adenocarcinoma of pancreas	19.60	15.46	4	14128	19	29560376
Cholecystitis chronic	19.44	15.46	9	14123	827	29559568
Impaired gastric emptying	19.05	15.46	14	14118	3056	29557339
Euglycaemic diabetic ketoacidosis	18.64	15.46	13	14119	2617	29557778
Gallbladder enlargement	18.33	15.46	9	14123	942	29559453
Pancreatectomy	17.93	15.46	4	14128	31	29560364
Follicular thyroid cancer	17.86	15.46	3	14129	3	29560392
Anaemia	17.78	15.46	44	14088	200907	29359488
Confusional state	17.73	15.46	21	14111	127856	29432539
Supraventricular extrasystoles	17.33	15.46	13	14119	2928	29557467
Drug dose titration not performed	17.30	15.46	6	14126	258	29560137
Catheter site cellulitis	16.97	15.46	5	14127	126	29560269
Gallbladder disorder	16.86	15.46	17	14115	5683	29554712
Cholecystitis acute	15.98	15.46	16	14116	5303	29555092
Disease progression	15.53	15.46	10	14122	81906	29478489

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pancreatitis	2273.94	14.45	866	25201	58741	64413924
Pancreatitis acute	894.96	14.45	406	25661	42449	64430216
Nausea	617.94	14.45	1117	24950	784683	63687982
Diabetic ketoacidosis	557.78	14.45	262	25805	29583	64443082
Pancreatic carcinoma	550.96	14.45	193	25874	10180	64462485
Vomiting	358.29	14.45	725	25342	550392	63922273
Lipase increased	324.20	14.45	144	25923	14258	64458407
Blood glucose increased	320.02	14.45	286	25781	97787	64374878
Pancreatic carcinoma metastatic	232.77	14.45	77	25990	3401	64469264
Weight decreased	185.85	14.45	377	25690	285362	64187303
Eructation	184.93	14.45	85	25982	9106	64463559
Abdominal pain	183.20	14.45	395	25672	311980	64160685
Diabetes mellitus inadequate control	181.51	14.45	111	25956	21210	64451455
Glycosylated haemoglobin increased	177.64	14.45	99	25968	15920	64456745
Cholelithiasis	168.98	14.45	143	25924	45363	64427302
Ketoacidosis	168.60	14.45	73	25994	6790	64465875
Diarrhoea	158.88	14.45	643	25424	722061	63750604
Lactic acidosis	155.92	14.45	156	25911	61254	64411411
Adenocarcinoma pancreas	143.72	14.45	46	26021	1827	64470838
Hypoglycaemia	124.39	14.45	167	25900	89725	64382940
Acute kidney injury	121.76	14.45	428	25639	448812	64023853
Injection site erythema	115.95	14.45	143	25924	70657	64402008
Injection site urticaria	115.57	14.45	66	26001	11115	64461550
Papillary thyroid cancer	111.47	14.45	40	26027	2258	64470407
Euglycaemic diabetic ketoacidosis	108.72	14.45	50	26017	5360	64467305
Amylase increased	107.76	14.45	60	26007	9625	64463040
Injection site rash	94.82	14.45	66	26001	15676	64456989
Medullary thyroid cancer	90.40	14.45	19	26048	130	64472535
Decreased appetite	89.34	14.45	283	25784	281006	64191659
Injection site haematoma	87.39	14.45	39	26028	3897	64468768
Abdominal pain upper	82.08	14.45	203	25864	174827	64297838
Injection site pruritus	79.67	14.45	87	25980	37739	64434926
Blood glucose decreased	78.36	14.45	69	25998	23054	64449611
Pancreatitis necrotising	78.29	14.45	34	26033	3183	64469482
Dehydration	78.07	14.45	228	25839	216535	64256130
Toxicity to various agents	57.76	14.45	38	26029	363475	64109190
Pancreatic neoplasm	55.54	14.45	21	26046	1374	64471291
Neutropenia	54.00	14.45	15	26052	239609	64233056
Drug ineffective	53.22	14.45	169	25898	840078	63632587
Thyroid mass	53.20	14.45	26	26041	3191	64469474
Injection site reaction	51.66	14.45	78	25989	46586	64426079
Thyroid neoplasm	48.56	14.45	23	26044	2634	64470031
Pyrexia	47.15	14.45	97	25970	558547	63914118
Flatulence	45.86	14.45	64	26003	35602	64437063
Febrile neutropenia	45.66	14.45	10	26057	187647	64285018
Joint swelling	44.04	14.45	16	26051	215366	64257299
Pancreatic carcinoma stage IV	43.57	14.45	14	26053	563	64472102
Pancreatic pseudocyst	42.88	14.45	17	26050	1264	64471401
Dyspepsia	42.83	14.45	98	25969	80214	64392451
Completed suicide	42.10	14.45	19	26048	224395	64248270
Impaired gastric emptying	41.86	14.45	32	26035	8772	64463893
Weight loss poor	41.06	14.45	15	26052	891	64471774
Cholecystitis acute	40.70	14.45	35	26032	11325	64461340
Constipation	39.25	14.45	190	25877	229147	64243518
Cholangiocarcinoma	38.52	14.45	18	26049	2000	64470665
Hyperglycaemia	37.74	14.45	79	25988	60889	64411776
Haemoglobin decreased	37.39	14.45	16	26051	195047	64277618
Drug dose titration not performed	37.36	14.45	13	26054	670	64471995
Reversible cerebral vasoconstriction syndrome	35.97	14.45	18	26049	2324	64470341
Glycosylated haemoglobin decreased	34.76	14.45	12	26055	604	64472061
Infusion related reaction	33.98	14.45	12	26055	164455	64308210
Pancreatitis chronic	33.95	14.45	20	26047	3566	64469099
Treatment failure	33.37	14.45	4	26063	116812	64355853
Thyroid cancer	31.97	14.45	20	26047	3971	64468694
Death	31.92	14.45	95	25972	482610	63990055
White blood cell count decreased	31.79	14.45	12	26055	157825	64314840
Platelet count decreased	31.76	14.45	14	26053	167697	64304968
Anaemia	31.68	14.45	66	26001	378614	64094051
Abdominal distension	31.68	14.45	98	25969	95896	64376769
Pancreatic mass	31.64	14.45	14	26053	1370	64471295
Pneumonia	30.97	14.45	119	25948	559457	63913208
Thrombocytopenia	30.89	14.45	27	26040	223774	64248891
Leukopenia	30.11	14.45	3	26064	101239	64371426
Ketosis	29.66	14.45	12	26055	941	64471724
Gastrooesophageal reflux disease	29.42	14.45	87	25980	83056	64389609
Blood glucose abnormal	27.04	14.45	25	26042	8888	64463777
Pancreatic enzymes increased	26.98	14.45	12	26055	1189	64471476
Metastases to liver	26.46	14.45	40	26027	23901	64448764
Pain	25.56	14.45	126	25941	553385	63919280
Pancreatic cyst	25.13	14.45	13	26054	1799	64470866
Cholecystitis	24.89	14.45	35	26032	19601	64453064
Rheumatoid arthritis	23.67	14.45	19	26048	164275	64308390
Blood calcitonin increased	23.57	14.45	5	26062	36	64472629
Bile duct stone	23.46	14.45	18	26049	4960	64467705
Injection site hypersensitivity	23.15	14.45	12	26055	1667	64470998
Drug titration error	23.09	14.45	10	26057	930	64471735
Tonsillar ulcer	23.01	14.45	8	26059	411	64472254
Disease progression	22.20	14.45	15	26052	141665	64331000
Ductal adenocarcinoma of pancreas	21.44	14.45	6	26061	149	64472516
Goitre	21.31	14.45	17	26050	4956	64467709
Neutrophil count decreased	21.19	14.45	3	26064	77193	64395472
Drug intolerance	21.09	14.45	27	26040	187965	64284700
Glomerular filtration rate decreased	20.65	14.45	32	26035	19540	64453125
Bile acid malabsorption	20.52	14.45	6	26061	175	64472490
Malignant neoplasm progression	20.46	14.45	10	26057	112861	64359804
Product contamination with body fluid	20.44	14.45	3	26064	0	64472665
Contraindicated product administered	20.41	14.45	9	26058	107820	64364845
Pleural effusion	20.37	14.45	13	26054	126546	64346119
Injection site pain	20.26	14.45	94	25973	111314	64361351
Therapeutic product effect decreased	19.76	14.45	11	26056	115340	64357325
Thyroid cyst	19.66	14.45	7	26060	386	64472279
Obstructive pancreatitis	19.44	14.45	8	26059	655	64472010
Ludwig angina	19.25	14.45	6	26061	218	64472447
Hyperlipasaemia	19.25	14.45	9	26058	1001	64471664
Increased appetite	19.07	14.45	22	26045	10124	64462541
Palpitations	18.88	14.45	88	25979	104400	64368265
Breath odour	18.49	14.45	10	26057	1514	64471151
Aerococcus urinae infection	18.36	14.45	3	26064	3	64472662
Injection site nodule	18.19	14.45	13	26054	3217	64469448
Pancreatic neuroendocrine tumour	18.18	14.45	7	26060	481	64472184
Injection site irritation	18.15	14.45	13	26054	3227	64469438
Benign neoplasm of thyroid gland	17.99	14.45	8	26059	792	64471873
Arthralgia	17.99	14.45	105	25962	442155	64030510
Gastroenteritis	17.80	14.45	38	26029	29673	64442992
Arthropathy	17.41	14.45	14	26053	120953	64351712
Blood glucose fluctuation	16.72	14.45	16	26051	5939	64466726
Hepatic steatosis	16.70	14.45	38	26029	30969	64441696
Glossodynia	16.66	14.45	3	26064	64693	64407972
Blood ketone body increased	16.43	14.45	7	26060	625	64472040
Diabetic ketosis	16.41	14.45	6	26061	357	64472308
C-reactive protein increased	16.33	14.45	9	26058	94900	64377765
Device malfunction	16.10	14.45	27	26040	17606	64455059
Cholecystectomy	16.08	14.45	18	26049	8014	64464651
Gastrointestinal haemorrhage	15.90	14.45	18	26049	132294	64340371
Agitation	15.76	14.45	8	26059	88359	64384306
Nasopharyngitis	15.68	14.45	35	26032	196038	64276627
Diabetic neuropathy	15.63	14.45	15	26052	5586	64467079
Imminent abortion	15.62	14.45	3	26064	12	64472653
Dysgeusia	15.48	14.45	48	26019	46999	64425666
Product quality issue	15.48	14.45	36	26031	29763	64442902
Hypoglycaemic unconsciousness	15.42	14.45	8	26059	1113	64471552
Diabetic metabolic decompensation	15.41	14.45	11	26056	2717	64469948
Biliary colic	15.25	14.45	12	26055	3432	64469233
Pemphigus	15.24	14.45	3	26064	60698	64411967
Extrasystoles	15.22	14.45	16	26051	6642	64466023
Depressed level of consciousness	15.09	14.45	7	26060	81429	64391236
Urogenital infection fungal	15.07	14.45	3	26064	15	64472650
Supraventricular extrasystoles	14.94	14.45	15	26052	5900	64466765
Somnambulism	14.79	14.45	14	26053	5127	64467538
Pancytopenia	14.65	14.45	22	26045	143287	64329378
Electrocardiogram QT prolonged	14.46	14.45	7	26060	79441	64393224

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A10AE56	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES INSULINS AND ANALOGUES Insulins and analogues for injection, long-acting
ATC	A10BJ02	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Glucagon-like peptide-1 (GLP-1) analogues
FDA CS	M0160181	Glucagon-Like Peptide 1
FDA MoA	N0000020058	Glucagon-like Peptide-1 (GLP-1) Agonists
MeSH PA	D006728	Hormones
MeSH PA	D007004	Hypoglycemic Agents
MeSH PA	D054795	Incretins
FDA EPC	N0000178480	GLP-1 Receptor Agonist
CHEBI has role	CHEBI:63726	neuroprotective agents
CHEBI has role	CHEBI:71196	GLP-1 receptor agonist

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Diabetes mellitus type 2	indication	44054006	DOID:9352
Weight loss	indication	89362005
Disorder of thyroid gland	contraindication	14304000	DOID:50
Multiple endocrine neoplasia, type 2	contraindication	61808009
Pancreatitis	contraindication	75694006	DOID:4989
C-cell hyperplasia of thyroid	contraindication	237552009
Hypoglycemic disorder	contraindication	237630007
Medullary thyroid carcinoma	contraindication	255032005	DOID:3973
Pregnancy, function	contraindication	289908002
Breastfeeding (mother)	contraindication	413712001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.06	acidic
pKa2	3.31	acidic
pKa3	3.67	acidic
pKa4	3.82	acidic
pKa5	4.11	acidic
pKa6	4.44	acidic
pKa7	9.65	acidic
pKa8	11.84	acidic
pKa9	12.2	acidic
pKa10	12.53	acidic
pKa11	12.59	acidic
pKa12	12.81	acidic
pKa13	12.86	acidic
pKa14	12.94	acidic
pKa15	13.1	acidic
pKa16	13.15	acidic
pKa17	13.2	acidic
pKa18	13.29	acidic
pKa19	13.43	acidic
pKa20	13.56	acidic
pKa21	13.56	acidic
pKa22	13.6	acidic
pKa23	13.71	acidic
pKa24	13.82	acidic
pKa25	13.82	acidic
pKa26	13.96	acidic
pKa27	13.97	acidic
pKa28	11.05	Basic
pKa29	10.45	Basic
pKa30	7.87	Basic
pKa31	5.98	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
18MG/3ML (6MG/ML)	VICTOZA	NOVO NORDISK INC	N022341	Jan. 25, 2010	RX	SOLUTION	SUBCUTANEOUS	6268343	Aug. 22, 2022	A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
18MG/3ML (6MG/ML)	SAXENDA	NOVO	N206321	Dec. 23, 2014	RX	SOLUTION	SUBCUTANEOUS	6268343	Aug. 22, 2022	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
18MG/3ML (6MG/ML)	VICTOZA	NOVO NORDISK INC	N022341	Jan. 25, 2010	RX	SOLUTION	SUBCUTANEOUS	9968659	Jan. 9, 2037	METHOD OF REDUCING THE RISK OF CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION, AND/OR NON-FATAL STROKE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE BY ADMINISTERING LIRAGLUTIDE
18MG/3ML (6MG/ML)	SAXENDA	NOVO	N206321	Dec. 23, 2014	RX	SOLUTION	SUBCUTANEOUS	9968659	Jan. 9, 2037	CARDIOVASCULAR OUTCOMES TRIAL OF LIRAGLUTIDE 1.8 MG IN PATIENTS WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
18MG/3ML (6MG/ML)	VICTOZA	NOVO NORDISK INC	N022341	Jan. 25, 2010	RX	SOLUTION	SUBCUTANEOUS	June 17, 2022	NEW PATIENT POPULATION
18MG/3ML (6MG/ML)	VICTOZA	NOVO NORDISK INC	N022341	Jan. 25, 2010	RX	SOLUTION	SUBCUTANEOUS	Dec. 17, 2022	PEDIATRIC EXCLUSIVITY
18MG/3ML (6MG/ML)	SAXENDA	NOVO	N206321	Dec. 23, 2014	RX	SOLUTION	SUBCUTANEOUS	Dec. 4, 2023	NEW PATIENT POPULATION

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Glucagon-like peptide 1 receptor	GPCR	P43220	GLP1R_HUMAN	AGONIST	EC50	10.20		WOMBAT-PK	CHEMBL

External reference:

ID	Source
D06404	KEGG_DRUG
4029703	VANDF
C1456408	UMLSCUI
CHEBI:71193	CHEBI
CHEMBL4524066	ChEMBL_ID
CHEMBL1201866	ChEMBL_ID
D000069450	MESH_DESCRIPTOR_UI
DB06655	DRUGBANK_ID
1133	IUPHAR_LIGAND_ID
8208	INN_ID
839I73S42A	UNII
16134956	PUBCHEM_CID
1598264	RXNORM
166619	MMSL
232503	MMSL
26647	MMSL
d07466	MMSL
010773	NDDF
444828003	SNOMEDCT_US
444907006	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Saxenda	HUMAN PRESCRIPTION DRUG LABEL	1	0169-2800	INJECTION, SOLUTION	6 mg	SUBCUTANEOUS	NDA	28 sections
Xultophy 100/3.6	HUMAN PRESCRIPTION DRUG LABEL	2	0169-2911	INJECTION, SOLUTION	3.60 mg	SUBCUTANEOUS	BLA	27 sections
Victoza	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4060	INJECTION	6 mg	SUBCUTANEOUS	NDA	28 sections
Victoza	HUMAN PRESCRIPTION DRUG LABEL	1	50090-2853	INJECTION	6 mg	SUBCUTANEOUS	NDA	28 sections
Saxenda	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4257	INJECTION, SOLUTION	6 mg	SUBCUTANEOUS	NDA	28 sections
Victoza	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4503	INJECTION	6 mg	SUBCUTANEOUS	NDA	28 sections